| 摘要 |
The invention provides a combination therapy for the treatment of multiple sclerosis (MS) in a subject in need thereof comprising administering cladribine and laquinimod. The cladribine and/or the laquinimod may be administered orally, intravenously or subcutaneously. However, it is preferred that both the cladribine and the laquinimod are administered subcutaneously. The cladribine and the laquinimod may be administered simultaneously. Alternatively, the administration of cladribine precedes the administration of laquinimod or the administration of laquinimod precedes the administration of cladribine. More preferably, the administration of cladribine and laquinimod continues for more than 30 days. In another aspect, a pharmaceutical composition comprising cladribine or a pharmaceutically acceptable salt or hydrate thereof, and laquinimod or a pharmaceutically acceptable salt or hydrate thereof for use in the treatment of MS. The composition may comprise a carrier and the laquinimod may be present as laquinimod sodium. |
